PTP
ONCT

Platform Technology Partners’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Platform Technology Partners’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$59K Buy
+598
New +$37.8K 0.03% 222

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Platform Technology Partners's ONCT Position: Q4 2020 in Review

Platform Technology Partners opened a new position in Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2020: 598 shares worth $59K. The stake represents 0.03% of the portfolio and ranks #222 among its holdings.

52 funds tracked by Wall St. Rank hold ONCT as of Q4 2020.

  • Platform Technology Partners held 598 shares of Oncternal Therapeutics, Inc. Common Stock worth $59K as of Q4 2020.
  • Oncternal Therapeutics, Inc. Common Stock was a new Platform Technology Partners position in Q4 2020.
  • Oncternal Therapeutics, Inc. Common Stock made up 0.03% of Platform Technology Partners's portfolio in Q4 2020, its #222 holding.
  • 52 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Platform Technology Partners's 13F filing for Q4 2020, filed 9 Feb 2021.